---
title: "ascend-cml"
date: "2024-08-24"
tags:
  - building
---

> [!NOTE]
> ðŸŒ± created from: [[treatment of chronic myelogenous leukemia (CML)]]

# ascend-cml

ASC4FIRST: Asciminib (80 mg once daily) vs. Investigator-selected TKI, Major molecular response at week 48: 67.7% vs. 49.0% (difference, 18.9 percentage points; 95% CI, 9.6 to 28.2; adjusted two-sided P<0.001); 38.0% grade 3 or higher adverse events with asciminib vs. 44.4% with imatinib and 54.9% with second-generation TKIs.

> Major molecular response æ¯”è¼ƒå¿«

[Asciminib in Newly Diagnosed Chronic Myeloid Leukemia | New England Journal of Medicine](https://www.nejm.org/doi/abs/10.1056/NEJMoa2400858)
